Navigation Links
Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium
Date:9/8/2011

LAUSANNE, Switzerland, September 8, 2011 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, will present tomorrow the 'Debiopharm Group Life Sciences Award 2011' to Professor Stefano Piccolo as well as two inaugural 'Junior Debiopharm Group Life Sciences Awards 2011' to Professor Etienne Meylan and Doctor Volker Busskamp. The award ceremony will take place at the EPFL (Ecole polytechnique fédérale de Lausanne) during the ISREC (Swiss Institute for Experimental Cancer Research) 2011 Life Sciences Symposium entitled 'Hallmarks and horizons of cancer'.

The 'Debiopharm Group Life Sciences Award 2011' is granted to Professor Stefano Piccolo from the University of Padua, Italy. He has made extensive contributions to the field of cancer, in particular in dissecting the role of a protein secreted by cells called "transforming growth factor beta (TGFb)", and the relation of TGFb to intracellular signalling pathways involved in cancer initiation and progression. Professor Piccolo is now working on the role of small RNAs called microRNAs or miRNAs in controlling overall cell signalling. The award amounts to CHF 50'000.- of which CHF 40'000.- are made available to the awardee's institute, whilst CHF 10'000.- are for personal use.

This year, Debiopharm decided to launch the inaugural 'Junior Debiopharm Group Life Sciences Awards'. Professor Etienne Meylan from the EPFL and Doctor Volker Busskamp from the Basel-based Friedrich Miescher Institute for Biomedical Research (FMI), are the recipients of the 'Junior Debiopharm Group Life Sciences Awards'. Each award amounts to CHF 25'000.- of which CHF 20'000.- are made available to the awardees' respective institutes, whilst CHF 5'000.- are for personal use. The junior awards are destined to young researchers in Switzerland, in the field of cellular and molecular biology. They are ideally at the stage of late postdoctoral studies or launching an independent research group. The selection criteria are based on excellence in previous work and originality of future projects.

Professor Meylan has just been appointed tenure-track Professor at the EPFL, following his postdoctoral work in the laboratory of Professor Tyler Jacks at MIT. His laboratory at the EPFL focuses on developing mouse models of lung cancer to test new promising anti-cancer compounds.

Doctor Busskamp recently completed a spectacular Ph.D. thesis in applied neuroscience at the FMI (Dr. Botond Roska's laboratory). During his Ph.D., he developed and validated a new type of therapy to repair blind retinas in vivo.

"Today's nominees all provided high quality and innovative work, allowing the jury to reach a unanimous decision," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "We are happy to recognise and reward these young scientists for their accomplishments. We wish them all the best and hope their research will lead to major discoveries in the medical field in the years to come."

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact    
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41-(0)21-321-01-11
Fax: +41-(0)21-321-01-69
mwagner@debiopharm.com

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44-(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Lena Evans
Account Executive
Tel:  +1-212-845-4262
Fax: +1-212-845-4260
lena.evans@russopartnersllc.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):